Navigation Links
The FDA has approved ankle replacements, so why don't all insurance plans cover them?
Date:6/4/2009

MAYWOOD, Il. -- It's been a decade since the U.S. Food and Drug Administration approved the first total ankle-replacement system for patients with severe ankle arthritis.

But several insurance companies still deny coverage, Loyola University Health System orthopaedic surgeon Dr. Michael Pinzur writes in a FootForum commentary in Foot & Ankle International, the official journal of the American Orthopaedic Foot and Ankle Society.

"It seems curious that the FDA agrees with the [foot and ankle society] that total ankle replacement is a reasonable treatment option . . . while several insurance providers do not find ankle replacement as a reasonable treatment option for ankle arthritis," Pinzur writes in the June issue.

An ankle replacement is an option for certain patients who suffer severe osteoarthritis, rheumatoid arthritis or injury-related arthritis that does not respond to more conservative treatments. In such patients, arthritis has destroyed cartilage, so the ankle joint is bone-on-bone.

An ankle replacement is similar to a knee or hip replacement. An implant is attached to the bottom of the tibia (shinbone) and to the talus (the first large bone of the foot). The smooth plastic surface of the tibial implant rotates on the polished metal surface of the talar implant.

Since approving the first total ankle-replacement system in 1999, the FDA has approved two other systems and given tentative approval to a third system. In 2003, the American Orthopaedic Foot and Ankle Society issued a statement that said a total ankle replacement "is a viable option for the treatment of ankle arthritis." And Medicare routinely covers ankle replacements.

Nevertheless, several insurance companies still deny coverage. They base their decision on a "meta-analysis" that concluded an ankle replacement was not a preferred treatment option. The meta-analysis compiled data from previous studies. It was sponsored by insurance companies and based on studies published in 2002 or earlier, Pinzur wrote.

"Should insurance companies make decisions on what treatments are appropriate and what treatments are deemed experimental?" Pinzur's commentary asks.


'/>"/>

Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System
Source:Eurekalert

Related medicine news :

1. $52.5 Million Settlement Against Sepracor Inc. Approved
2. FDA Cracks Down on Unapproved Cough Medicines
3. Video: New FDA-Approved Sun Protectant Saves Skin All Year Round
4. Optometry-Backed Vision Care for Kids Act Approved by U.S. House
5. Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis
6. A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks
7. Barrs Generic Version of Estrostep(R) Fe Tablets Approved
8. PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy
9. Pennsylvania American Waters Rate Case Approved
10. RNs Statement on Death of Nataline Sarkisyan: CIGNA Should Have Listened to her Doctors and Approved the Transplant a Week Ago
11. Hiemstra Approved to Manufacture Medical Devices in New CER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... 21, 2017 , ... The Margarian Law Firm has filed a class ... ale for allegedly containing no ginger. Dr. Pepper produces the “Canada Dry” brand of ... Margaryan alleges Canada Dry Ginger Ale claims on its bottle that it is made ...
(Date:7/21/2017)... ... July 21, 2017 , ... “Kids aren't born knowing how to ... shoes,” says Suzanne Tucker, Founder of St. Louis-based positive education company Generation Mindful. To ... Kickstarter on Monday, July 21st. , The kit uses colorful, engaging and educational ...
(Date:7/21/2017)... CANADA (PRWEB) , ... July 21, 2017 , ... ... torn anterior cruciate ligament (ACL) offer patients improved quality of life five years ... for Sports Medicine’s Annual Meeting in Toronto, Ontario, Canada. The study followed ...
(Date:7/20/2017)... Boston, MA (PRWEB) , ... July 20, 2017 ... ... aggressive form of blood and bone marrow cancer that progresses rapidly without treatment. ... often recommended to reduce the chance of reoccurrence and relapse. With such ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... in which their iMedSecure™ comes included with each system installation. RMT’s iMedHD2™ ... to remote participants for real-time collaboration and immediate decision-making requirements. While never ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... 2017  New York City-based market research firm Kalorama Information ... aware of.  From new products to new costs, to the ... recently completed study, Potential Pipeline Disruptors . ... 1.  Age-Driven Growth - True Impact Moment Arriving ... the impact the growing population and, to a more extreme ...
(Date:7/11/2017)... ROCKVILLE, Md. , July 11, 2017  The ... had estimated revenues of approximately $394.1 million in 2016.  ... a trend of solid growth, in particular as a ... oncology clinical practice, and the recent introduction of a ... the need for less-invasive testing of tumor biomarkers to ...
(Date:7/10/2017)... GAITHERSBURG, Md. , July 10, 2017 ... in non-animal test methods, is the recipient of a ... by the PETA International Science Consortium. The device, which ... be used to expose human lung cells to airborne ... lung. IIVS will use the VITROCELL® system for testing ...
Breaking Medicine Technology: